The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
MOMENTUM: Pemvidutide Boasts "Class-Leading" Lean Mass Preservation with Weight Loss
June 23rd 2024MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.